17 research outputs found

    Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination

    Get PDF
    BACKGROUND AND OBJECTIVES: Acute inflammatory CNS diseases include neuromyelitis optica spectrum disorders (NMOSDs) and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD). Both MOGAD and acute disseminated encephalomyelitis (ADEM) have been reported after vaccination. Consequently, the mass SARS-CoV-2 vaccination program could result in increased rates of these conditions. We described the features of patients presenting with new acute CNS demyelination resembling NMOSDs or MOGAD within 8 weeks of SARS-CoV-2 vaccination. METHODS: The study included a prospective case series of patients referred to highly specialized NMOSD services in the UK from the introduction of SARS-CoV-2 vaccination program up to May 2022. Twenty-five patients presented with new optic neuritis (ON) and/or transverse myelitis (TM) ± other CNS inflammation within 8 weeks of vaccination with either AstraZeneca (ChAdOx1S) or Pfizer (BNT162b2) vaccines. Their clinical records and paraclinical investigations including MRI scans were reviewed. Serologic testing for antibodies to myelin oligodendrocyte glycoprotein (MOG) and aquaporin 4 (AQP4) was performed using live cell–based assays. Patients' outcomes were graded good, moderate, or poor based on the last clinical assessment. RESULTS: Of 25 patients identified (median age 38 years, 14 female), 12 (48%) had MOG antibodies (MOGIgG+), 2 (8%) had aquaporin 4 antibodies (AQP4IgG+), and 11 (44%) had neither. Twelve of 14 (86%) antibody-positive patients received the ChAdOx1S vaccine. MOGIgG+ patients presented most commonly with TM (10/12, 83%), frequently in combination with ADEM-like brain/brainstem lesions (6/12, 50%). Transverse myelitis was longitudinally extensive in 7 of the 10 patients. A peak in new MOGAD cases in Spring 2021 was attributable to postvaccine cases. Both AQP4IgG+ patients presented with brain lesions and TM. Four of 6 (67%) seronegative ChAdOx1S recipients experienced longitudinally extensive TM (LETM) compared with 1 of 5 (20%) of the BNT162b2 group, and facial nerve inflammation was reported only in ChAdOx1S recipients (2/5, 40%). Guillain-Barre syndrome was confirmed in 1 seronegative ChAdOx1S recipient and suspected in another. DISCUSSION: ChAdOx1S was associated with 12/14 antibody-positive cases, the majority MOGAD. MOGAD patients presented atypically, only 2 with isolated ON (1 after BNT162b2 vaccine) but with frequent ADEM-like brain lesions and LETM. Within the seronegative group, phenotypic differences were observed between ChAdOx1S and BNT162b2 recipients. These observations might support a causative role of the ChAdOx1S vaccine in inflammatory CNS disease and particularly MOGAD. Further study of this cohort could provide insights into vaccine-associated immunopathology

    Antibody agonists trigger immune receptor signaling through local exclusion of receptor-type protein tyrosine phosphatases

    Get PDF
    Antibodies can block immune receptor engagement or trigger the receptor machinery to initiate signaling. We hypothesized that antibody agonists trigger signaling by sterically excluding large receptor-type protein tyrosine phosphatases (RPTPs) such as CD45 from sites of receptor engagement. An agonist targeting the costimulatory receptor CD28 produced signals that depended on antibody immobilization and were sensitive to the sizes of the receptor, the RPTPs, and the antibody itself. Although both the agonist and a non-agonistic anti-CD28 antibody locally excluded CD45, the agonistic antibody was more effective. An anti–PD-1 antibody that bound membrane-proximally excluded CD45, triggered SHP2 phosphatase recruitment, and suppressed systemic lupus erythematosus and delayed-type hypersensitivity in experimental models. Paradoxically, nivolumab and pembrolizumab, anti–PD-1 blocking antibodies used clinically, also excluded CD45 and were agonistic in certain settings. Reducing these agonistic effects using antibody engineering improved PD-1 blockade. These findings establish a framework for developing new and improved therapies for autoimmunity and cancer

    The effect of manipulating apoptotic cell uptake on their immunogenicity

    Get PDF
    Failure of the immune system to differentiate between apoptotic tumour cells and cells rendered apoptotic as part of homeostasis prevents a successful response being mounted against tumours. Apoptotic cells are cleared rapidly by professional phagocytes thus preventing the release of potentially inflammatory or immunogenic material into the surrounding environment. In addition, macrophages release immuno-suppressive cytokines such as tumour growth factor ? (TGF-?) and interleukin-10 (IL-10) that dampen the initiation of cytotoxic T cell (CTL) immunity and render T cells tolerant. It was hypothesised that manipulation of this clearance pathway, which is normally employed to prevent autoimmunity, may alleviate immuno-suppression of apoptotic tumour cells and promote the expansion of a tumour antigen-specific T cell response.Milk fat globule – epidermal growth factor 8 (MFG-E8) is a glycoprotein secreted by activated macrophages and immature dendritic cells. It facilitates the uptake of apoptotic cells by acting as a bridging molecule between integrins on the phagocyte and phosphatidylserine (PS) on the apoptotic cell surface. Here, two recombinant dominant-negative MFG-E8 proteins were generated: one which is shown to inhibit PS-dependent apoptotic cell uptake by macrophages by over 40% (DN-MFG-E8), and a second which re-directed apoptotic cells through Fc? receptors and conferred enhanced phagocytosis by both macrophages and immature dendritic cells (DN-MFG-E8-Fc) in a dose-dependent manner.Cross-presentation of cell-associated antigen by bone marrow-derived dendritic cells (BMDCs) was determined by CD8+ T cell proliferation assays in vitro and in vivo. Loading BMDCs with apoptotic cells via a PS-independent pathway or through Fc? receptors (Fc?Rs) reduced their ability to induce CD8+ T cell proliferation in vivo, suggesting the blockade of a mechanism which is intrinsic for DC maturation or migration. Similarly, the balance between activating and inhibitory Fc?Rs proved essential for effective DC maturation. Apoptotic cells treated with DN-MFG-E8-Fc protein resulted in upregulation of costimulatory molecules, CD86 and CD70, when BMDCs were deficient for the inhibitory Fc?R, Fc?RIIb.Additionally, the immunosuppressive effect of apoptotic cells on antibody production proved dependent on the exposure of PS; whereby both DN-MFG-E8 and DN-MFG-E8-Fc proteins were shown to alleviate this suppression

    Invariant NKT cells promote CD8(+) cytotoxic T cell responses by inducing CD70 expression on dendritic cells

    No full text
    Activation of invariant NK T (iNKT) cells with the glycolipid alpha-galactosylceramide promotes CD8(+) cytotoxic T cell responses, a property that has been used to enhance the efficacy of antitumor vaccines. Using chimeric mice, we now show that the adjuvant properties of iNKT cells require that CD40 triggering and Ag presentation to CD8(+) T cells occur on the same APCs. We demonstrate that injection of alpha-galactosylceramide triggers CD70 expression on splenic T cell zone dendritic cells and that this is dependent on CD40 signaling. Importantly, we show that blocking the interaction between CD70 and CD27, its costimulatory receptor on T cells, abrogates the ability of iNKT cells to promote a CD8(+) T cell response and abolishes the efficacy of alpha-GalCer as an adjuvant for antitumor vaccines. These results define a key role for CD70 in linking the innate response of iNKT cells to the activation of CD8(+) T cells

    Mouse fetal growth restriction through parental and fetal immune gene variation and intercellular communications cascade.

    No full text
    Fetal growth restriction (FGR) affects 5-10% of pregnancies, and can have serious consequences for both mother and child. Prevention and treatment are limited because FGR pathogenesis is poorly understood. Genetic studies implicate KIR and HLA genes in FGR, however, linkage disequilibrium, genetic influence from both parents, and challenges with investigating human pregnancies make the risk alleles and their functional effects difficult to map. Here, we demonstrate that the interaction between the maternal KIR2DL1, expressed on uterine natural killer (NK) cells, and the paternally inherited HLA-C*0501, expressed on fetal trophoblast cells, leads to FGR in a humanized mouse model. We show that the KIR2DL1 and C*0501 interaction leads to pathogenic uterine arterial remodeling and modulation of uterine NK cell function. This initial effect cascades to altered transcriptional expression and intercellular communication at the maternal-fetal interface. These findings provide mechanistic insight into specific FGR risk alleles, and provide avenues of prevention and treatment
    corecore